Cesa™ Stat OCA0025695 reduces electric charges with a sustainable antistatic effect and keeps the surface dust-free and clean.

MEVOPUR COLORANTS • Standard colors in PP and PE to shorten time-to-market • Custom colors matched to Pantone, RAL or other color reference • White colorants for pharmaceutical packaging for LDPE, HDPE and PP with opacity to reach USP chapter MEVOPUR FUNCTIONAL ADDITIVES • Antistatic formulation with good flow/impact for injection molding • Amide- and amine-free antistatic for film in contact with API (Active Pharmaceutical Ingredients) • UV blocking for transparent PP and PE packaging to meet USP chapter • Non-migrating friction reduction/processing aid for PE and PP • Laser marking/welding additive for fast, reliable marking/assembly • MVTR (Moisture Vapor Transmission Rate) reduction for HDPE to improve shelf-life • Thermal protection of the polymer during processing • Gamma/e-beam sterilization protection for PP (up to 50kGy) with color compensation for reduced yellowing REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request Bormed™ is a registered trademark of Borealis Healthcare use limitations apply—see below.

The Avient team worked with the manufacturer to meet specific property needs and developed a customized solution that added soft-touch, ergonomic, and friction-free features.

Processors are looking to replace current process additives containing PFAS with non-PFAS fluorine-free solutions that exhibit performance characteristics similar to traditional fluoropolymer- based solutions.

We continue to generate strong cash flow from operations and are maintaining our full year free cash flow guidance of $180 million. This reflects the confidence we have in our ability to continue to deliver consistent free cash flow, but more importantly to drive long-term earnings growth from the areas of focus we highlighted at our Sustainability Day in September.” The non-GAAP financial measures include adjusted EPS, adjusted operating income, adjusted gross margin, adjusted EBITDA, and free cash flow.

The non-GAAP financial measures include: adjusted EPS, adjusted operating income, free cash flow and adjusted EBITDA. Avient does not provide reconciliations of forward-looking non-GAAP financial measures, such as outlook for Adjusted EBITDA, Adjusted Earnings Per Share, Adjusted Operating Income and Free Cash Flow, to the most comparable GAAP financial measures on a forward-looking basis because Avient is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. Global Compact & fulfilled Communication of Progress (COP) requirements • New Sustainability Strategy overview page including our 2022 AIP ESG metrics • New ESG Performance page with ESG ratings, awards, and certifications • Increased disclosures on carbon emissions, including disclosure of Climate Change Scenario Analysis • Added new Product Stewardship and Chemical Management policies • Enhanced data reporting for Workforce Demographics • Improved social disclosures on human rights, dependent care and special leave and strategic training management 2021 SUSTAINABILITY REPORT Launching integrated sustainability website in parallel with report Aligned with leading reporting frameworks 13 ESG PERFORMANCE & AWARDS 14 16th ENVIRONMENTAL SOCIAL GOVERNANCE 2 1 3 (as of 6/30/22) 2022 O U T LO O K $429 $490 2021 2022E $3.05 $3.50 2021 2022E FY 2022 GUIDANCE (TOTAL COMPANY: CURRENT PORTFOLIO) 16 Sales Adjusted Operating Income $4,819 $5,100 2021 2022E + 6% Adjusted EPS + 14% + 15% (in millions) (in millions) (+ 9% excluding FX) (+ 18% excluding FX) (+ 20% excluding FX) 17 CASH FLOW / LEVERAGE ($ millions) 2022E Cash Flow from Operating Activities 400$ Less: Run-Rate CapEx (90) CapEx for Clariant Integration (10) CapEx for IT System Upgrade (15) Total CapEx (115) Free Cash Flow 285$ Adjusted EBITDA 635$ Net Debt / Adjusted EBITDA 1.6x 18 DYNEEMA / DISTRIBUTION UPDATES • Strong performance so far in 2022 in-line with our modeling • Acquisition to be finalized as early as September 1, pending standard regulatory process and closing conditions • Encouraging interest thus far from potential buyers for world-class business with a strong track record • Second round bids due in August DISTRIBUTION 19 PRO FORMA MODELING UPDATE 2022E ($M) Revenue 5,100$ 415$ 5,515$ (1,635)$ 3,880$ Adjusted EBITDA 635 130 765 (109) 656 EBITDA % 12% 31% 14% 7% 17% Adj.

LIMITED WARRANTY Subject to paragraph 3, and unless otherwise expressly provided herein, Seller warrants good and free title and that the Product will conform to Seller's published specifications, if any, or those other quality standards and/or measurements set forth herein. Seller shall replace, free of charge, any Products which do not conform to these specifications in one or several deliveries.

Use of Non-GAAP Measures Page 3 PolyOne Commodity to Specialty Transformation • Volume driven, commodity producer • Heavily tied to cyclical end markets • Performance largely dependent on non- controlling joint ventures 2000-2005 2006 - 2009 2010 – 2014 2015 and beyond • Steve Newlin appointed, Chairman, President and CEO • New leadership team appointed • Implementation of four pillar strategy • Focus on value based selling, investment in commercial resources and innovation to drive transformation • 18 consecutive quarters of double- digit adjusted EPS growth • Shift to faster growing, high margin, less cyclical end markets • Key acquisitions propel current and future growth, as well as margin expansion • Established aggressive 2015 targets • Continue specialty transformation • Targeting $2.50 Adjusted EPS by 2015, nearly double 2013 EPS • Drive double digit operating income and adjusted EPS growth Confirmation of Our Strategy The World’s Premier Provider of Specialized Polymer Materials, Services and Solutions Specialization Globalization Operational Excellence Commercial Excellence -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% 450.00% PolyOne S&P 500 Russell 2000 Dow Jones Chemical All time high of $39.28 April 4th, 2014 • 18 consecutive quarters of double digit EPS growth • 49% CAGR adjusted EPS expansion 2006-2013 • 2013 stock price increased 73% versus 30% growth in the S&P • More than seven fold increase in market cap: $0.5b $3.6b Strategy and Execution Drive Results Page 6 Appliance 4% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 5% Consumer 10%Packaging 16% Industrial 12% HealthCare 11% Transportation 18% Misc. 2% 0.12 0.27 0.21 0.13 0.68 0.82 1.00 1.31 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010 2011 2012 2013 2015 Target Ad ju st ed E ar ni ng s P er S ha re 2013 Revenues: $3.8 Billion End Markets 2013 Revenues: $3.8 Billion EPS Page 7 PolyOne At A Glance United States 67% Europe 14% Canada 7% Asia 6% Latin America 6% Specialty 54% PP&S 18% Distribution 28% Mix Shift Highlights Specialty Transformation Page 8 Old PolyOne Transformation *Operating Income excludes corporate charges and special items 2% 34% 43% 62% 64% 0% 20% 40% 60% 80% 100% 2005 2008 2010 2013 Q1 2014 2015 % o f O pe ra tin g In co m e* JV's Performance Products & Solutions Distribution Specialty 65-75% Specialty OI $5M $46M $87M $195M $60M Target 2015 Target Proof of Performance & 2015 Goals Page 9 2006 Q1 2014 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 13.8% 12 – 16% Global Specialty Engineered Materials 1.1% 11.6% 12 – 16% Designed Structures & Solutions -- 6.5% 8 – 10% Performance Products & Solutions 5.5% 7.7% 9 – 12% Distribution 2.6% 6.1% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 64% 65 – 75% 3) ROIC* (after-tax) 5.0% 9.4% 15% 4) Adjusted EPS Growth N/A 42% Double Digit Expansion *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Bridge to $2.50 Adjusted EPS by 2015 2015 EPS: $2.50 2013 EPS: $1.31 Continued Gross Margin Expansion Mergers & Acquisitions Spartech Accretion Incremental share buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Several Levers to Drive Growth Mid single digit revenue CAGR Innovation Drives Earnings Growth $20.3 $52.3 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* *Percentage of Specialty Platform revenue from products introduced in last five years Page 11 14.3% 30.7% 2006 2013 Specialty Platform Gross Margin % 19.5% 42.0% 2006 Q1 2014 Healthcare Consumer Packaging and Additive Technology Transportation Page 12 Unique and Innovative Solutions https://www.dropbox.com/sh/dwe4t8aacvhb8ui/uD3p_bdglP/Presentation revise pics/GLS Beverage can closure XO 2.jpg https://www.dropbox.com/sh/dwe4t8aacvhb8ui/-YgkycKypw/Anti-Counterfeiting release & images/GN1979.JPG 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2014 Pension Funding** As of March 31, 2014 Debt Maturities & Pension Funding – 3/31/14 Net Debt / EBITDA* = 1.9x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of March 31, 2014 ($ millions) Coupon Rates: 7.500% 7.375% 5.250% ** includes US-qualified pension plans only *TTM 3/31/2014 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return $0.16 $0.20 $0.24 $0.32 $0.10 $0.20 $0.30 $0.40 2011 2012 2013 2014 Annual Dividend  Expanding our sales, marketing, and technical capabilities  Investing in operational and initiatives that drive profitability growth Manufacturing realignment  Targets that expand our: • Specialty offerings • End market presence • Geographic footprint • Operating Margin  Synergy opportunities  Adjacent material solutions  Repurchased 1.4 million shares in Q1 2014  Repurchased 6.4 million shares since April 2013  13.6 million shares are available for repurchase under the current authorization Organic Growth Acquisitions Share Repurchases Dividends The New PolyOne: A Specialty Growth Company Why Invest In PolyOne? ���PolyOne Investor Presentation�5th Annual Wells Fargo�Industrial and Construction Conference �May 8, 2014 �� Forward – Looking Statements Use of Non-GAAP Measures PolyOne Commodity to Specialty Transformation Confirmation of Our Strategy Strategy and Execution Drive Results PolyOne�At A Glance Mix Shift Highlights Specialty Transformation Proof of Performance & 2015 Goals Bridge to $2.50 Adjusted EPS by 2015 Innovation Drives Earnings Growth Unique and Innovative Solutions Debt Maturities & Pension Funding – 3/31/14 Free Cash Flow and Strong Balance Sheet �Fund Investment / Shareholder Return Why Invest In PolyOne?

S&P 500 -150% -50% 50% 150% 250% 350% 450% 550% POL S&P 500 All time high of $43.34 July 1st, 2014 PolyOne Corporation Page 9 2006 2014 YTD 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 14.9% 12 – 16% Global Specialty Engineered Materials 1.1% 12.1% 12 – 16% Designed Structures & Solutions -- 7.6% 8 – 10% Performance Products & Solutions 5.5% 8.1% 9 – 12% Distribution 2.6% 6.2% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 65% 65 – 75% 3) ROIC* 5.0% 10.6% 15% 4) Adjusted EPS Growth N/A 37% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period PolyOne Corporation Page 10 32% Adjusted EPS CAGR from 2011 2015 EPS: $2.50 2011 EPS: $0.82 Continued Gross Margin Expansion Mergers & Acquisitions Spartech Accretion Incremental Share Buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Several Levers to Drive Growth Mid Single Digit Revenue Growth PolyOne Corporation Page 11 Innovation Drives Earnings Growth *Percentage of Specialty Platform revenue from products introduced in last five years $20 $53 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* 14% 31% 2006 2013 Specialty Platform Gross Margin % 20% 43% 2006 2013 Specialty Vitality Index Target ≥ 35% Vitality Products + 700 to 1000 bps PolyOne Corporation Page 12 Prototype Frame Opportunity Scale-up & Test Market Build Business Case Commercial Launch Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 4 11 5 10 6 9 3 4 2 15 9 1 10 4 Breakthrough Platform Derivative A Rich Pipeline of Opportunity Number of Projects 25 14 19 17 18 93 Addressable Market ($ millions) TBD TBD $800 $450 $450 $1,700 PolyOne Corporation Page 13 Megatrends Aligned with Key End Markets Decreasing Dependence on Fossil Fuels Protecting the Environment Improving Health and Wellness Megatrend End Markets Globalizing and Localizing Health & Wellness Transportation Packaging Consumer PolyOne Corporation Page 14 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2014 Pension Funding** As of September 30, 2014 Debt Maturities & Pension Funding – 9/30/14 Net Debt / EBITDA* = 1.7x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of September 30, 2014 ($ millions) Coupon Rates: 7.500% 7.375% 5.250% ** includes US-qualified pension plans only *TTM 9/30/2014 PolyOne Corporation Page 15 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return Expanding our sales, marketing, and technical capabilities Targets that expand our: • Specialty offerings • End market presence • Geographic footprint • Operating Margin Synergy opportunities Adjacent material solutions Repurchased 1.5 million shares in Q3 2014 Repurchased 9.7 million shares since early 2013  10.3 million shares are available for repurchase under the current authorization Organic Growth Acquisitions Share Repurchases Dividends  Investing in operational and LSS initiatives (including synergy capture) Manufacturing alignment $0.16 $0.20 $0.24 $0.32 $0.40 $0.10 $0.20 $0.30 $0.40 $0.50 2011 2012 2013 2014 2015 Annual Dividend PolyOne Corporation Page 16 PolyOne Core Values Innovation Collaboration Excellence PolyOne Corporation Page 17 The New PolyOne: A Specialty Growth Company Why Invest In PolyOne? ��PolyOne Investor Presentation�Goldman Sachs 2014 US Emerging / SMID Cap Growth Conference�New York, NY�November 20, 2014�� Forward-Looking Statements Use of Non-GAAP Measures PolyOne Commodity to Specialty Transformation PolyOne�At A Glance Mix Shift Highlights Specialty Transformation Confirmation of Our Strategy Strategy and Execution Drive Results Proof of Performance & 2015 Goals 32% Adjusted EPS CAGR from 2011 Innovation Drives Earnings Growth A Rich Pipeline of Opportunity Megatrends Aligned with Key End Markets Debt Maturities & Pension Funding – 9/30/14 Free Cash Flow and Strong Balance Sheet �Fund Investment / Shareholder Return PolyOne Core Values Why Invest In PolyOne?

The non-GAAP financial measures include organic performance (which excludes the impact of foreign exchange), adjusted EPS, adjusted operating income, adjusted EBITDA, adjusted EBITDA margins, free cash flow and adjusted free cash flow. Three Months Ended December 31, Year Ended December 31, Reconciliation to Consolidated Statements of Income: 2024 2023 2024 2023 Sales $ 746.5 $ 719.0 $ 3,240.4 $ 3,142.8 Gross margin - GAAP 259.5 208.9 1,056.7 892.5 Special items in gross margin (Attachment 3) (23.3) 17.6 (0.7) 80.0 Adjusted gross margin $ 236.2 $ 226.5 $ 1,056.0 $ 972.5 Adjusted gross margin as a percent of sales 31.6 % 31.5 % 32.6 % 30.9 % Operating income - GAAP 85.6 43.1 329.3 196.8 Special items in operating income (Attachment 3) (20.4) 26.1 21.4 116.0 Adjusted operating income $ 65.2 $ 69.2 $ 350.7 $ 312.8 Adjusted operating income as a percent of sales 8.7 % 9.6 % 10.8 % 10.0 % Three Months Ended December 31, Year Ended December 31, Reconciliation to EBITDA and Adjusted EBITDA: 2024 2023 2024 2023 Net income from continuing operations – GAAP $ 48.5 $ 27.6 $ 170.7 $ 76.3 Income tax expense (benefit) 14.8 (7.0) 54.1 11.0 Interest expense 25.5 26.8 105.6 115.3 Depreciation and amortization from continuing operations 45.4 44.2 179.7 188.8 EBITDA from continuing operations $ 134.2 $ 91.6 $ 510.1 $ 391.4 Special items, before tax (23.9) 22.4 20.1 114.6 Interest expense included in special items — (0.1) (2.3) (2.3) Depreciation and amortization included in special items (0.3) — (1.5) (1.9) Adjusted EBITDA $ 110.0 $ 113.9 $ 526.4 $ 501.8 Adjusted EBITDA as a percent of sales 14.7 % 15.8 % 16.2 % 16.0 % Three Months Ended March 31, 2024 Reconciliation to Condensed Consolidated Statements of Income $ EPS(1) Net income from continuing operations attributable to Avient shareholders $ 49.4 $ 0.54 Special items, after-tax 5.5 0.06 Amortization expense, after-tax 14.9 0.16 Adjusted net income / EPS $ 69.8 $ 0.76 (1) Per share amounts may not recalculate from figures presented herein due to rounding 14 Year Ended December 31, Adjusted Free Cash Flow Calculation 2024 2023 Cash provided by operating activities $ 256.8 $ 201.6 Taxes paid on gain on sale of business — 104.1 One-time payout associated with deferred compensation plans 20.8 — Adjusted cash provided by operating activities $ 277.6 $ 305.7 Capital expenditures (121.9) (119.4) Adjusted free cash flow $ 155.7 $ 186.3